Decompensated cirrhosis affects over 10 million people worldwide and is the cause of mortality of about 2 million people yearly. Death rates remain largely unchanged, despite escalating healthcare costs. The clinical and prognostic models of decompensated cirrhosis have been studied extensively in the past 20 years, leading up to the identification of a newly defined clinical entity: acute-on chronic liver failure.
Emerging data from studies on the pathophysiological basis of decompensated cirrhosis has identified systemic inflammation as being central to the progression of liver disease and mortality. This new understanding is leading to rapid changes in the approaches to the management of cirrhotic patients, design of clinical trials, and selection of patients for early liver transplantation. In recognition of the exciting new developments in the field, EASL and the Journal of Hepatology have published a special Supplement summarising the current literature authored by leaders in the field. These two EASL webinars have been designed to allow the authors to critically discuss recent advances in decompensated cirrhosis with the audience.
This first webinar will take place 25 May 2021, 18:00–19:30 CET.
- Understand the changing epidemiology of cirrhosis
- Learn about new perspectives in the trajectory of cirrhosis and why acute on chronic liver failure should be considered a distinct clinical entity
- Understand the role of systemic inflammation and how this fits into the established pathophysiological mechanisms of decompensated cirrhosis
- Understand how the management of decompensated cirrhosis is changing, the concept of disease modifying agents and issue of working beyond guidelines
- How sarcopenia and frailty impact on outcomes, their assessment and therapeutic approaches
- Exploring nuances in the intensive care management of patients with ACLF and the role of liver transplantation
|Prof. Rajiv Jalan||University College London Medical School|
|Prof. Gyongyi Szabo||Beth Israel Deaconess Medical Center|
|Prof. Peter Jepsen||University of Aarhus|
|Prof. Thierry Gustot||Université Libre de Bruxelles|
|Prof. Jonel Trebicka||University Goethe Frankfurt am Main|
|Dr. Shilpa Chokshi||Institute of Hepatology and Foundation for Liver Research|
|18:00 – 18:05||Welcome and Introduction||Rajiv Jalan / Gyongyi Szabo|
|18:05 – 18:20||Changing Epidemiology and Healthcare burden||Peter Jepsen|
|18:20 – 18:35||Disease Trajectory and New tools for stratification||Thierry Gustot|
|18:35 – 18:50||Pathophysiological basis of Decompensated Cirrhosis||Jonel Trebicka|
|18:50 – 19:05||Immune dysfunction in cirrhosis||Shilpa Chokshi|
|18:05 – 19:30||Discussion and Q&A||All|
Journal of Hepatology Supplement
Publication of the supplement was supported financially by CSL Behring. The sponsor had no involvement in content development, the decision to submit the manuscript or in the acceptance of the manuscript for publication.
Cirrhosis & Complications at ILC 2021
At ILC 2021, this track presents an overview of the role of vessels in liver diseases. The track content will include not only the role of liver sinusoidal changes in liver disease progression, but also the management of portal and hepatic vein thrombosis and their complications. The management of complications of portal hypertension will also be addressed, including the place of transjugular intrahepatic portosystemic shunt (TIPS) and the management of patients with advanced cirrhosis and acute-on-chronic liver failure (ACLF).